




Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma



MONDAY, OCTOBER 27, 2025 | COLOGNE, GERMANY

12:00 – 12:10

INTRODUCTION

Philippe Moreau and Hermann Einsele

12:10 – 13:10

ADVANCES IN DIAGNOSTICS

Chairs: Hartmut Goldschmidt, Annamaria Brioli, Cyrus Khandanpour

12:10 – 12:20

Breakout Lesions/EMD

Niels Weinhold

12:20 – 12:30

Single Cell Spatial Organization of Tumor Microenvironment

Leo Rasche

12:30 – 12:40

Advances in MRD Detection: Peripheral Blood and Bone Marrow Strategies

Paula Tabares

12:40 – 12:50

Monitoring for Infectious Post-T-Cell-Based Therapy

Heinz Ludwig

12:50 – 13:00

Predictors of Response and Mechanisms of Relapse

Marc Raab

13:00 – 13:10

Discussion

13:10 – 14:10

TREATMENT WITH NOVEL AGENTS/NOVEL COMBINATIONS/ NOVEL CONCEPTS

Chairs: Maria Krauth, Martin Gramatzki, Christof Scheid

13:10 – 13:20

CeIMOD (Combinations)

Monica Engelhardt

13:20 - 13:30

1 Line Therapy with Belamaf + Future Options

Katja Weisel

13:30 - 13:40

2 Line Therapy with Belamaf/Occular Management

Martin Kortüm

13:40 - 13:50

Bispecific Combinations/Trispecifics

Ralph Wäsch

13:50 - 14:00

CART Cells in Earlier Lines

Holger Auner

14:00 – 14:10

Discussion

14:10 – 14:40

BREAK

14:40 – 15:45	MANAGEMENT OF COMPLICATIONS <i>Chairs: Klaus Podar, Hans Salwender, Sebastian Theurich</i>
14:40 – 14:50	CIDP Post-Cilta-cel Jan Krönke
14:50 – 15:00	Immune Effector Cell Associated Secondary Malignancies Johannes Waldschmidt
15:00 – 15:10	Bridging Therapies Jan Frenking
15:10 – 15:20	Relapse Management Christoph Driessen
15:20 – 15:30	Modulation of the Target Antigen Florian Bassermann
15:30 – 15:45	Discussion

15:45 – 16:00	FINAL WORDS Philippe Moreau and Hermann Einsele
---------------	---

The International Myeloma Society gratefully acknowledges the following organizations for their support of the workshop:

PLATINUM

Johnson & Johnson

GOLD

 Bristol Myers Squibb®

GSK